GNTLF Genetic Technologies Ltd (PK)

 

 

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

dated March 6, 2024

 

Commission File Number 0-51504

 

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name)

 

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐ No ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: March 7, 2024

 

	GENETIC TECHNOLOGIES LIMITED
	By:	/s/ Tony Di Pietro
	Name:	Tony Di Pietro
	Title:	Company Secretary

 

 

EXHIBIT INDEX

 

Exhibit		Description of Exhibit
99.1		Change of Director’s Interest Notice

 

 

 

Exhibit 99.1

 

Appendix 3Y

Change of Director’s Interest Notice

 

Rule 3.19A.2

 

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

 

Introduced 30/09/01 Amended 01/01/11

 

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director	Peter Irwin Rubenstein
Date of last notice	27 December 2023

 

Part 1 - Change of director’s relevant interests in securities

 

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Irwin Biotech Nominees Pty Ltd <BIO A/C>
Date of change		From 29 February to 6 March 2024.
No. of securities held prior to change		Irwin Biotech Nominees Pty Ltd <BIO A/C> 870,494 Ordinary shares   Irwin Biotech Nominees Pty Ltd 20,000 Ordinary shares 865,827 Ordinary shares (represented by 28,861 American Depositary Receipts)   RIP Opportunities Pty Ltd 75,000 Ordinary shares (represented by 2,500 American Depositary Receipts)   RIP Opportunities Pty Ltd <PIR Super Fund A/C> 1,250,000 Ordinary shares

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

Class		Ordinary shares
Number acquired		617,209
Number disposed		Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$80,315.18, an average of approximately 13 cents per ordinary share.
No. of securities held after change		Irwin Biotech Nominees Pty Ltd <BIO A/C> 1,487,703 Ordinary shares   Irwin Biotech Nominees Pty Ltd 20,000 Ordinary shares 865,827 Ordinary shares (represented by 28,861 American Depositary Receipts)   RIP Opportunities Pty Ltd 75,000 Ordinary shares (represented by 2,500 American Depositary Receipts)   RIP Opportunities Pty Ltd <PIR Super Fund A/C> 1,250,000 Ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		On Market Trades

 

 

Appendix 3Y

Change of Director’s Interest Notice

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract		N/A
Nature of interest		N/A
Name of registered holder (if issued securities)		N/A
Date of change		N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed		N/A
Interest acquired		N/A
Interest disposed		N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation		N/A
Interest after change		N/A

 

Part 3 – +Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?		No
If so, was prior written clearance provided to allow the trade to proceed during this period?		N/A
If prior written clearance was provided, on what date was this provided?		N/A

 

---